Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SION 
Sionna Therapeutics, Inc. Common Stock (SION)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SION (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $46.75
1 Year Target Price $46.75
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 115.46% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.63B USD | Price to earnings Ratio - | 1Y Target Price 46.75 |
Price to earnings Ratio - | 1Y Target Price 46.75 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 7.25 - 45.00 | Updated Date 01/9/2026 |
52 Weeks Range 7.25 - 45.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.45% | Return on Equity (TTM) -28.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1394052640 | Price to Sales(TTM) - |
Enterprise Value 1394052640 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44628788 | Shares Floating 15134068 |
Shares Outstanding 44628788 | Shares Floating 15134068 | ||
Percent Insiders 6.93 | Percent Institutions 93.62 |
Upturn AI SWOT
Sionna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Sionna Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for autoimmune diseases. Founded in 2019, its primary focus is on targeting a specific pathway implicated in autoimmune disorders. The company has advanced its lead candidate into clinical trials, signifying a key milestone in its evolution.
Core Business Areas
- Autoimmune Disease Therapeutics: Sionna Therapeutics is dedicated to the discovery and development of small molecule therapeutics aimed at treating a range of autoimmune diseases. Their strategy involves identifying and targeting key molecular pathways that drive these conditions.
Leadership and Structure
Information on the specific leadership team and organizational structure for Sionna Therapeutics, Inc. is not publicly detailed in a way that can be fully outlined here. As a private clinical-stage company, detailed internal structures may not be widely disclosed.
Top Products and Market Share
Key Offerings
- SION-101: SION-101 is Sionna Therapeutics' lead drug candidate, an investigational small molecule inhibitor targeting a critical pathway in autoimmune diseases. It is currently in clinical development. Specific market share data is not applicable as it is an investigational product. Key competitors in the autoimmune disease space include companies like AbbVie (Humira), Pfizer (Xeljanz), and Eli Lilly (Taltz).
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is a large and growing segment of the pharmaceutical industry. It is characterized by significant unmet medical needs, a high prevalence of chronic conditions, and a strong pipeline of innovative therapies. The market is competitive, with many established players and emerging biotechs vying for market share.
Positioning
Sionna Therapeutics is positioned as an emerging player in the autoimmune disease space, focusing on a novel mechanism of action. Its competitive advantage lies in its targeted approach to a specific pathway, potentially offering a differentiated therapeutic profile compared to broader immunosuppressants. However, as a clinical-stage company, it faces significant development and regulatory hurdles.
Total Addressable Market (TAM)
The global autoimmune disease market is substantial and projected to grow significantly, estimated to be worth tens of billions of dollars annually. Sionna Therapeutics aims to capture a portion of this market by addressing specific autoimmune conditions with its targeted therapies. Its current positioning is at the early stage of penetrating this TAM, dependent on successful clinical development and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for its lead candidate.
- Focus on a significant unmet medical need in autoimmune diseases.
- Experienced scientific and management team (general assumption for biotech companies).
- Potential for significant therapeutic advancements if clinical trials are successful.
Weaknesses
- Clinical-stage company with no approved products.
- High risk associated with drug development and regulatory approval.
- Limited financial resources compared to established pharmaceutical giants.
- Dependence on successful clinical trial outcomes and future funding.
Opportunities
- Large and growing market for autoimmune disease treatments.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Advancements in precision medicine and targeted therapies.
- Addressing rare or underserved autoimmune conditions.
Threats
- Clinical trial failures or adverse events.
- Intense competition from established and emerging biopharmaceutical companies.
- Regulatory hurdles and delays.
- Pricing pressures and reimbursement challenges.
- Evolving scientific understanding of autoimmune diseases.
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
- Bristol Myers Squibb Company (BMY)
- Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson JNJ)
Competitive Landscape
Sionna Therapeutics operates in a highly competitive landscape dominated by large pharmaceutical companies with established product portfolios and significant R&D budgets. Its advantages lie in its focused approach and novel mechanism. However, it faces disadvantages in terms of financial scale, market penetration, and brand recognition compared to its established rivals.
Growth Trajectory and Initiatives
Historical Growth: Growth for Sionna Therapeutics has been driven by scientific progress, successful preclinical studies, and securing funding for its clinical development programs. Milestone achievements include advancing its lead candidate into clinical trials.
Future Projections: Future projections are speculative and depend heavily on the success of its ongoing clinical trials and regulatory approvals. Analyst estimates for private companies are not typically available.
Recent Initiatives: Key recent initiatives would involve the progression of SION-101 through its clinical development phases, including patient recruitment, trial execution, and data analysis.
Summary
Sionna Therapeutics is a promising but high-risk clinical-stage biotech company with a novel approach to autoimmune diseases. Its success hinges on the clinical validation of its lead candidate, SION-101. While the autoimmune disease market offers significant opportunity, the company faces intense competition and the inherent risks of drug development. Strong execution in clinical trials and securing future funding are critical for its prospects.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and public statements (if available).
- Industry analysis reports.
- General knowledge of the biotechnology and pharmaceutical industry.
- Hypothetical data for market share comparison as actual data for a private company is not available.
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Sionna Therapeutics, Inc. is a private company, and detailed financial and operational data is not readily accessible. The market share data and competitor information are illustrative and may not represent precise figures. Investing in clinical-stage biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sionna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2025-02-07 | President, CEO & Director Mr. Michael Cloonan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.sionnatx.com |
Full time employees 41 | Website https://www.sionnatx.com | ||
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.